These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 11533626)
21. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering? Purnhagen KP Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663 [No Abstract] [Full Text] [Related]
22. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
23. Industry reneges on postmarketing trial commitments. Bouchie A Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074 [No Abstract] [Full Text] [Related]
24. Spinning the wheel on ImClone. Varchaver N Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651 [No Abstract] [Full Text] [Related]
25. 2006 drug approvals: finding the niche. Owens J Nat Rev Drug Discov; 2007 Feb; 6(2):99-101. PubMed ID: 17342860 [No Abstract] [Full Text] [Related]
26. An audience with Thomas Lönngren. Interview by Asher Mullard. Lönngren T Nat Rev Drug Discov; 2010 Dec; 9(12):912. PubMed ID: 21119726 [No Abstract] [Full Text] [Related]
27. Introduction: public and private sector collaboration in the field of contraceptive research and development. Segal S Rev Law Soc Change; 1997; 23(3):329-37. PubMed ID: 10725051 [No Abstract] [Full Text] [Related]
28. An industry imperiled by regulatory bottlenecks. Naughton G Nat Biotechnol; 2001 Aug; 19(8):709-10. PubMed ID: 11479550 [No Abstract] [Full Text] [Related]
29. Industry and regulatory performance in 2012: a year in review. Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160 [TBL] [Abstract][Full Text] [Related]
32. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry. O'Reilly JT Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328 [No Abstract] [Full Text] [Related]
33. What ever happened to FDAMA Section 114? A look back after 10 years. Neumann PJ Value Health; 2009; 12(2):189-90. PubMed ID: 18657100 [No Abstract] [Full Text] [Related]
34. FDA to steer nanotech. Fox JL Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060 [No Abstract] [Full Text] [Related]
35. The pharmaceutical industry. Lewis L; Siegelman S State Health Care Am; 1993; ():42-9. PubMed ID: 10168060 [TBL] [Abstract][Full Text] [Related]
36. Overhauling oversight--European drug legislation. Tsang L Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389 [TBL] [Abstract][Full Text] [Related]